Inclusion Criteria:

1. For dose escalation study, patients must have histological confirmation of solid
tumors that is metastatic or unresectable. For expansion cohorts, patients must have
metastatic or unresectable GIST, melanoma, or uncategorized tumors that are positive
for c-KIT mutations. KIT positive tumors will be confirmed in original biopsied
tumors and biopsied tumors acquired during this study. This analysis will be done by
CLIA approved mutational analysis which will likely include isolation of genomic DNA
from tumor, polymerase chain reaction (PCR) amplification of exons of interest of
c-KIT gene, bidirectional sequencing of PCR amplicons, and computational analysis of
sequences to determine mutation presence or absence.

2. Patients who have completed previous therapies 4-weeks prior to (or within 5 drug
half lives) enrollment on study. Radiation therapy wash out period will be 2 weeks.
This includes an exception of patients with metastatic GIST tumors who are taking
maintenance imatinib mesylate therapy. These patients are allowed to remain on
imatinib mesylate therapy up to enrollment in this study.

3. Age > or = 15 years

4. ECOG performance status < 2 (Karnofsky > 60%).

5. Patients must have normal organ and marrow function as defined below: leukocytes >
3,000/mcL; absolute neutrophil count >1,500/mcL; platelets > 100,000/mcL, total
bilirubin < or = 2.0 mg/dL. (Does NOT apply to patients with Gilbert's Syndrome);
AST(SGOT)/ALT(SGPT) < 2.5 X institutional upper limit of normal (patients with liver
involvement will be allowed < or = 5.0 X institutional upper normal limit) serum
creatinine < 2.0 mg/dL

6. Patients MUST have recovered from all treatment related toxicities to Grade 1 NCI
CTCAE (v 4.0) in severity

7. Patients must be willing and able to review, understand, and provide written consent
before starting therapy

8. Patients with histologically proven intracranial glioblastoma, gliosarcoma or
anaplastic astrocytoma will be eligible. Patients must have shown unequivocal
radiographic evidence for tumor progression by MRI scan. A scan should be performed
within 14 days prior to registration and on a steroid dose that has been stable for
at least 5 days. If the steroid dose is increased between the date of imaging and
registration, a new baseline MRI is required.

Exclusion Criteria:

1. Autoimmune disease: Patients with a history of inflammatory bowel disease (including
Crohn's disease and ulcerative colitis) and autoimmune disorders such as rheumatoid
arthritis, systemic progressive sclerosis [scleroderma], Systemic Lupus Erythematosus
or autoimmune vasculitis [e.g., Wegener's Granulomatosis] are excluded from this
study.

2. History of acute diverticulitis, intra-abdominal abscess, GI obstruction, abdominal
carcinomatosis or other known risk factors for bowel perforation.

3. Any underlying medical or psychiatric condition, which in the opinion of the
Investigator, will make the administration of study drug hazardous or obscure the
interpretation of Adverse Events (AEs): e.g. a condition associated with frequent
diarrhea or chronic skin conditions, recent surgery or colonic biopsy from which the
patient has not recovered, or partial endocrine organ deficiencies.

4. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, history of congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.

5. Known HIV, Hepatitis B, or Hepatitis C.

6. Any non-oncology vaccine therapy used for prevention of infectious diseases (for up
to one month prior to or after any dose of ipilimumab).

7. Concomitant therapy with any of the following: IL-2, interferon or other non-study
immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; other
investigational therapies; or chronic use of systemic corticosteroids (used in the
management of cancer or non-cancer-related illnesses).

8. Patients who do not agree to practice appropriate birth control methods while on
therapy.

9. Pregnant women are excluded from this study. Women of child-bearing potential and men
must agree to use contraception prior to study entry and for the duration of study
participation. Should a woman become pregnant or suspect she is pregnant while
participating in this study, she should inform her treating physician.